# Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)

> **NCT05030350** · PHASE3 · TERMINATED · sponsor: **VistaGen Therapeutics, Inc.** · enrollment: 481 (actual)

## Conditions studied

- Social Anxiety Disorder

## Interventions

- **DRUG:** PH94B

## Key facts

- **NCT ID:** NCT05030350
- **Lead sponsor:** VistaGen Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-01
- **Primary completion:** 2022-09-23
- **Final completion:** 2022-09-23
- **Target enrollment:** 481 (ACTUAL)
- **Why stopped:** Study stopped by the sponsor for business reasons and not due to any safety concerns with PH94B
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05030350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05030350, "Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05030350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*